GSK
@gsk.bsky.social
We are uniting science, technology and talent to get ahead of disease together.
2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
November 28, 2025 at 3:55 PM
2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
“More years in life, and more life in those years."
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
November 28, 2025 at 1:00 PM
“More years in life, and more life in those years."
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
November 19, 2025 at 3:00 PM
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
November 19, 2025 at 10:00 AM
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
November 18, 2025 at 10:59 AM
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
November 11, 2025 at 3:08 PM
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
November 7, 2025 at 1:52 PM
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
October 30, 2025 at 2:00 PM
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
October 29, 2025 at 7:21 AM
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
October 28, 2025 at 7:15 AM
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz
October 28, 2025 at 7:07 AM
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz
#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer.
Find out more: gsk.to/4nrTYFX
Find out more: gsk.to/4nrTYFX
October 27, 2025 at 7:04 AM
#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer.
Find out more: gsk.to/4nrTYFX
Find out more: gsk.to/4nrTYFX
#News for #Investors and #Media
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
October 23, 2025 at 8:17 PM
#News for #Investors and #Media
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective.
➡️ Want to learn more? www.gsk.com/en-gb/innova...
➡️ Want to learn more? www.gsk.com/en-gb/innova...
October 22, 2025 at 8:46 AM
We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective.
➡️ Want to learn more? www.gsk.com/en-gb/innova...
➡️ Want to learn more? www.gsk.com/en-gb/innova...
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr
October 22, 2025 at 6:31 AM
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr
Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.
October 21, 2025 at 8:08 AM
Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.
#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/47egZpR
Learn more: gsk.to/47egZpR
October 21, 2025 at 7:00 AM
#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/47egZpR
Learn more: gsk.to/47egZpR
#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta.
Learn more: gsk.to/47h8tGN
Learn more: gsk.to/47h8tGN
October 21, 2025 at 6:17 AM
#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta.
Learn more: gsk.to/47h8tGN
Learn more: gsk.to/47h8tGN
Understanding the challenges faced by those living with gynaecologic cancers is key to driving change.
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
October 18, 2025 at 8:00 AM
Understanding the challenges faced by those living with gynaecologic cancers is key to driving change.
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB